Published 17 days ago • loading... • Updated 16 days ago

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Summary by Ground News

Ipsen, a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032. Following the disclosure of the Investment Grade ratings with BBB- from S&P and Baa3 from Moody’s, both with a stable outlook, this transaction was very well received and largely oversubscribed by a diversified and solid institutional investor base.

18 Articles

All

Left

Center

Right

Financial Times

Center

Ipsen announces issuance of €500 million inaugural Rated Public Bond – Company Announcement - FT.comIpsen announces issuance of €500 million inaugural Rated Public Bond

The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.

16 days ago·London, United Kingdom

Read Full Article

The Globe & Mail

+14 Reposted by 14 other sources

Center

Ipsen announces issuance of €500 million inaugural Rated Public Bond

GlobeNewswire Press Release.

17 days ago·Canada

Read Full Article

L'AGEFI

Ipsen diversifies its financing with a bond loan

With its withdrawal from the bond market since 2023, the pharmaceutical laboratory has met a strong demand for its issue of 500 million euros at seven years.

17 days ago

Read Full Article